Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Proteasome inhibitors, such as bortezomib, have significantly improved outcomes for multiple myeloma patients.
• Newer agents like carfilzomib are under investigation, alongside combinations with other chemotherapeutics.
• The clinical efficacy of proteasome inhibitors in solid tumors remains limited, despite their success in hematological malignancies.

Purpose of the Study:

• To explore the potential of proteasome inhibitors in treating solid tumors.
• To investigate the molecular mechanisms, including apoptosis and autophagy, underlying the efficacy of bortezomib and cisplatin.
• To identify novel therapeutic strategies for solid malignancies based on overcoming chemotherapy resistance.

Main Methods:

• Review of existing clinical trial data and preclinical research on proteasome inhibitors.
• Analysis of molecular pathways, focusing on apoptosis and autophagy, in response to bortezomib and cisplatin.
• Exploration of combination therapies involving proteasome inhibitors and other anticancer agents.

Main Results:

• Bortezomib and cisplatin demonstrate the ability to overcome chemotherapy resistance through modulation of apoptosis and autophagy.
• These mechanisms sensitize tumor cells, offering potential for enhanced anticancer therapy.
• Ongoing trials are evaluating proteasome inhibitors, including bortezomib, in combination regimens for solid tumors.

Conclusions:

• The molecular insights into bortezomib and cisplatin's action provide a basis for developing novel therapeutic strategies.
• Targeting apoptosis and autophagy pathways may enhance the effectiveness of proteasome inhibitors in solid tumors.
• Further research and clinical trials are crucial to realize the full potential of proteasome inhibitors in treating solid malignancies.